Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 11, 2026

Is Procter & Gamble (PG) Offering A Reasonable Entry Point After Recent Share Price Weakness?

View original at finance.yahoo.com
Is Procter & Gamble (PG) Offering A Reasonable Entry Point After Recent Share Price Weakness? Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Two-stage DCF model estimates PG intrinsic value at $185.60 per share, implying the stock trades at a 21.1% discount

    60% confidence

  • Analysts and internal estimates project PG free cash flow of $14.76 billion in 2026, rising to $21.13 billion in 2035, with analyst inputs through 2028 and Simply Wall St extrapolations thereafter

    60% confidence

  • Simply Wall St assigns Procter & Gamble a 4/6 valuation score

    60% confidence

  • Recent market attention on PG has centered on its household products staple status and how consumer companies are assessed amid changing spending patterns

    60% confidence

  • On a DCF methodology, Procter & Gamble screens as underpriced / undervalued

    60% confidence

  • 49 additional high-quality undervalued stocks are identified by Simply Wall St beyond Procter & Gamble

    60% confidence

Data points we hold from this source

Procter & Gamble · cash14.76 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com